This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.
Seralutinib (GB002)
Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
ATS - May 2023
TORREY TLR PLS
ATS - May 2023
See More
GB7208
A CNS-Penetrant BTK Inhibitor Modulates Multiple Pathogenic Pathways Implicated in Multiple Sclerosis
ACTRIMS - Feb 2023
GB7208 is a CNS-Penetrant BTK Inhibitor Demonstrating Potent Activity on Pathogenic Pathways Implicated in Multiple Sclerosis
ECTRIMS1 – October 2022
See More
Discovery Programs
Diacylglycerol Kinase Alpha and Zeta Dual Inhibitors Enhance T Cell Responses and Promote Robust and Durable Anti-Tumor T Cell Immunity
SITC - November 2022
See More